FrancophonIA/ELRC3.0 huggingface dataset:
English: In integrated Studies I and II, patients receiving reslizumab 3 mg/kg had significant reductions in asthma exacerbations (56% for subgroup GINA 4 and 5) compared to placebo.
Estonian: I ja II uuringu integreeritud tulemuste kohaselt vähenesid reslizumabi 3 mg/kg annuse saanud patsientidel astma ägenemised oluliselt (56% GINA 4. ja 5. astme alarühmas) võrreldes platseeboga.
English: Placebo (n=232)
Estonian: Platseebo (n = 232)
English: An infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding filter (pore size of 0.2 µm) should be used for infusion.
Estonian: Infundeerimiseks tuleb kasutada infusioonikomplekti, millel on voolikusisene, steriilne, mittepürogeenne, madala valgusiduvusega filter (poori suurus 0,2 µm).
English: This medicinal product must not be mixed with other medicinal products except sodium chloride 9 mg/mL (0.9%) solution for infusion.
Estonian: Seda ravimpreparaati ei tohi segada muude ravimpreparaatidega, v.a naatriumkloriidi 9 mg/ml (0,9%) infusioonilahusega.
English: For dosing instructions see section 4.2 of Summary of Product Characteristics.
Estonian: Annustamisjuhised vt Ravimi omaduste kokkuvõte, lõik 4.2.
English: CINQAERO is provided as a concentrate for solution for infusion in a single-use vial.
Estonian: CINQAERO't tarnitakse infusioonilahuse kontsentraadina ühekordselt kasutatavas viaalis.
English: CINQAERO should be administered by a healthcare professional prepared to manage hypersensitivity reactions including anaphylaxis (see section 4.4).
Estonian: CINQAERO't peab manustama tervishoiutöötaja, kes on kohe valmis osutama abi ülitundlikkusreaktsioonide, sh anafülaksia korral (vt lõik 4.4).
English: The proportion of patients who did not experience an asthma exacerbation during the 52-week treatment period was higher in the reslizumab 3 mg/kg group (62% and 75%) compared with the placebo group (46% and 55%), in Studies I and II, respectively.
Estonian: I ja II uuringus oli patsientide osakaal, kellel ei esinenud astma ägenemisi 52-nädalase raviperioodi ajal, suurem reslizumabi 3 mg/kg annuse rühmas (vastavalt 62% ja 75%) võrreldes platseeborühmaga (vastavalt 46% ja 55%).
English: One vial of 10 mL contains 100 mg reslizumab.
Estonian: Üks 10 ml viaal sisaldab 100 mg reslizumabi.
English: Systemic exposure to reslizumab appears to be unaffected by anti-reslizumab antibodies.
Estonian: Reslizumabivastased antikehad ei näi mõjutavat reslizumabi plasmakontsentratsiooni.
English: CINQAERO is supplied in glass vials containing 2.5 mL or 10 mL.
Estonian: CINQAERO't tarnitakse 2,5 ml või 10 ml klaasviaalis.
English: FEV1 (mL) Mean diff (95% CIb) (p-value)
Estonian: FEV1 (ml) Keskmine erinevus (95% CI
English: Preparation of solution for infusion
Estonian: Infusioonilahuse valmistamine
English: In Studies I and II, severe eosinophilic asthma is defined as any patients falling into GINA steps 4 and 5 (medium- to high-dose ICS [≥ 440 µg fluticasone propionate] plus another controller, with or without maintenance OCS) with a blood eosinophil count of ≥400 µL-1 at start of treatment.
Estonian: GINA 4. ja 5. astmesse (keskmine kuni suur annus suukaudset kortikosteroidi [≥ 440 µg flutikasoonpropionaati] koos mõne muu baasravimiga, kas koos säilitusravimina kasutatava suukaudse kortikosteroidiga või ilma selleta) ja kellel on ravi alguses vere eosinofiilide sisaldus ≥ 400 µl-1.
English: - The other excipients are sodium acetate, acetic acid glacial, sucrose and water for injections.
Estonian: - Teised abiained on naatriumatsetaat, jää-äädikhape, sahharoos ja süstevesi.
English: d The percentage of patients with refractory asthma (based on the American Thoracic Society
Estonian: d I ja II uuringus osalenud refraktaarse astmaga [American Thoracic Society (ATS) / European
English: Investigations
Estonian: I uuring
English: Particles might be present.
Estonian: Võib sisaldada tahkeid osakesi.
English: Proportions of patients in GINA steps 4 and 5c
Estonian: Patsientide osakaal, kes saavad GINA 4. ja 5. raviastme ravic
English: How to store CINQAERO
Estonian: Kuidas CINQAERO't säilitada
English: Effect on blood eosinophils
Estonian: Toime röga eosinofiilidele
English: CINQAERO 10 mg/mL concentrate for solution for infusion
Estonian: CINQAERO 10 mg/ml infusioonilahuse kontsentraat
English: Results were supported by the secondary efficacy endpoints and were in line with the overall population.
Estonian: Tulemusi, mis olid kooskõlas kõigi patsiendirühmadega, kinnitasid ka teisesed tulemusnäitajad.
English: Patients below 35 kg or above 199 kg
Estonian: Patsiendid kehakaaluga alla 35 kg või üle 199 kg Soovitatav annus on 3 mg kehakaalu kg kohta.
English: How CINQAERO is given
Estonian: Kuidas CINQAERO't manustatakse
English: Studies I and II
Estonian: I ja II uuring
English: Placebo (n=380)
Estonian: Platseebo (n 380)
English: The serious adverse reaction of anaphylactic reaction was reported and considered related to reslizumab in 3 patients (0.19%) during placebo-controlled and open-label asthma studies.
Estonian: Platseebo kontrolliga ja avatud astmauuringute ajal teatati raskest kõrvaltoimest anafülaktilisest reaktsioonist ja seda peeti reslizumabiga seotuks 3 patsiendil (0,19%).
English: CINQAERO 10 mg/mL concentrate for solution for infusion reslizumab
Estonian: CINQAERO 10 mg/ml infusioonilahuse kontsentraat reslizumabum
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 16 hours at 2 °C-8 °C, unless dilution has taken place in controlled and validated aseptic conditions.
Estonian: Ravimit võib säilitada kuni 16 tundi temperatuuril 2 kuni 8 °C, väljaarvatud juhul, kui lahjendamine on toimunud kontrollitud ja valideeritud aseptilistes tingimustes.
English: Asthma exacerbations were evaluated only in the exacerbation studies (Studies I and II: reslizumab
Estonian: Astma ägenemisi hinnati ainult ägenemiste uuringutes (I ja II uuring: reslizumab 3 mg/kg [n = 14] ja platseebo [n = 11]).
English: Anaphylactic reaction*
Estonian: Immuunsüsteemi häired aeg-ajalt anafülaktiline reaktsioon*
English: Reslizumab total dose (mg)
Estonian: Reslizumabi koguannus (mg)
English: Each mL of concentrate contains 10 mg of reslizumab.
Estonian: Üks ml kontsentraati sisaldab 10 mg reslizumabi.
English: CINQAERO contains sodium
Estonian: CINQAERO sisaldab naatriumi
English: Proteinaceous particles might be present.
Estonian: Võib sisaldada valkaine osakesi.
English: Sodium acetate trihydrate Acetic acid glacial Sucrose
Estonian: Naatriumatsetaattrihüdraat Jää-äädikhape Sahharoos
English: Upon completion of the infusion, flush the infusion set with sterile sodium chloride 9 mg/mL (0.9%) solution for infusion to ensure that all of the CINQAERO solution for infusion has been administered.
Estonian: Kogu CINQAERO infusioonilahuse manustamise tagamiseks loputage pärast infusiooni lõpetamist infusioonikomplekt läbi naatriumkloriidi 9 mg/ml (0,9%) steriilse infusioonilahusega.
English: Reslizumab has not been studied in patients with hepatic impairment.
Estonian: Reslizumabi ei ole uuritud maksafunktsiooni kahjustusega patsientidel.
English: Musculoskeletal and connective tissue disorders
Estonian: Lihas-skeleti ja sidekoe kahjustused aeg-ajalt müalgia*
English: Of these subjects, 1,006 asthma patients were exposed for at least 6 months, 759 exposed for at least 1 year and 237 exposed for longer than 2 years (up to 3 years).The following adverse reactions have been reported with reslizumab during placebo-controlled asthma studies for up to 52 weeks of treatment with a 3 mg/kg dose given intravenously (1,028 patients).
Estonian: Neist osalejaist said 1006 astmapatsienti ravi vähemalt 6 kuud, 759 vähemalt 1 aasta ja 237 kauem kui 2 aastat (kuni 3 aastat).
English: Malignancies
Estonian: Fertiilsus
English: Overall population Reslizumab 3 mg/kg (n=477)
Estonian: Reslizumab 3 mg/kg (n = 477)
English: If you miss your scheduled dose of CINQAERO
Estonian: Kui CINQAERO plaanitud annus jääb manustamata
English: Batch
Estonian: ACQ
English: No apparent deviation from dose-proportional reslizumab pharmacokinetics was noted over the dose range of 0.3 mg/kg to 3.0 mg/kg.
Estonian: Annusevahemikus 0,3...3,0 mg/kg ei täheldatud nähtavat kõrvalekallet reslizumabi annusega proportsionaalsest farmakokineetikast.
English: Data by study Study I
Estonian: Andmed uuringute kaupa
English: LIST OF EXCIPIENTS
Estonian: Ägenemiste anamnees
English: Renal Impairment
Estonian: VIAALI SILT
English: This is not unusual for proteinaceous solutions.
Estonian: See on valkaine osakesi sisaldavate lahuste puhul tavaline.
English: These can be taken from you or from a donor.
Estonian: Neid saab võtta teilt või doonorilt.
English: • think you may be pregnant; or
Estonian: • arvate, et võite olla rase;
English: It is therefore difficult to recommend an optimum method.
Estonian: Seetõttu on optimaalset meetodit soovitada raske.
English: Date of first authorisation: 06 February 2009 Date of latest renewal: 13 November 2013
Estonian: Müügiloa esmase väljastamise kuupäev: 06. veebruar 2009 Müügiloa viimase uuendamise kuupäev: 13. november 2013
English: 83607 Holzkirchen Germany
Estonian: 83607 Holzkirchen Saksamaa
English: These changes all reversed after discontinuation of treatment.
Estonian: Kõik need muutused taandusid pärast ravi lõpetamist.
English: The following information is intended for healthcare professionals only
Estonian: Järgmine teave on ainult tervishoiutöötajale:
English: Please tell your doctor immediately during treatment:
Estonian: Rääkige ravi ajal kohe oma arstile:
English: If you are a stem cell donor, you must be aged between 16 and 60 years.
Estonian: Kui olete tüvirakkude doonor, peate olema vanusevahemikus 16 kuni 60 aastat.
English: Your healthcare professional should always record the exact product you are using.
Estonian: Teie tervishoiutöötaja peab alati üles märkima konkreetse preparaadi, mida te kasutate.
English: This should be considered when interpreting boneimaging results.
Estonian: Seda tuleb luu-uuringute tulemuste tõlgendamisel arvesse võtta.
English: You, or people caring for you, can be taught how to give subcutaneous injections so that you can continue your treatment at home.
Estonian: Teile või teid hooldavale inimesele saab õpetada nahaaluste süstide tegemist, et saaksite ravi kodus jätkata.
English: EXP After dilution use within 24 hours.
Estonian: EXP Pärast lahjendamist kasutada 24 tunni jooksul.
English: Dose adjustment is not required in these circumstances.
Estonian: Seetõttu annuse kohandamine nimetatud asjaoludel ei ole vajalik.
English: It is advisable to wait and see how you feel after taking Filgrastim HEXAL and before driving or operating machinery.
Estonian: Soovitatav on oodata ja vaadata, kuidas te tunnete ennast pärast Filgrastim HEXAL saamist ja enne auto juhtimist või masinate käsitsemist.
English: Growth factors are proteins that are produced naturally in the body but they can also be made using biotechnology for use as a medicine.
Estonian: Kasvufaktorid on kehas loomulikult toodetavad valgud, kuid neid saab ravimina kasutamiseks luua ka biotehnoloogia abil.
English: Pharmacotherapeutic group: Immunostimulants, colony stimulating factors, ATC Code: L03AA02
Estonian: Farmakoterapeutiline rühm: immunostimulaatorid, kolooniaid stimuleerivad faktorid, ATC-kood: L03AA02
English: As with all therapeutic proteins, there is a potential for immunogenicity.
Estonian: Nagu teistegi terapeutiliste valkudega, on võimalik immunogeensuse tekkimine.
English: > 1.0 x 109/l for 3 consecutive days
Estonian: > 1,0 × 109/l kolmel järjestikusel päeval
English: 1995 - 2000b a Analysis includes studies involving BM transplant during this period; some studies used GM-CSF b Analysis includes patients receiving BM transplant during this period
Estonian: 1995-2000b a Analüüs hõlmab luuüdi transplantaadi uuringuid sel perioodil, mõnes uuringus kasutati GM-CSF-i b Analüüs hõlmab luuüdi transplantaadiga patsiente sel perioodil.
English: - if you are allergic to filgrastim or any of the other ingredients of this medicine (listed in section 6).
Estonian: - kui olete filgrastiimi või selle ravimi mis tahes koostisosa(de) (loetletud lõigus 6) suhtes allergiline.
English: Although this interaction has not been formally investigated, there is no evidence that such an interaction is harmful.
Estonian: Kuigi sellist koostoimet ei ole uuritud, puuduvad tõendid selle koostoime ohtlikkuse kohta.
English: Syringes are embossed with graduation rings in order to enable partial use if required.
Estonian: Süstaldele on märgitud jaotusringid, et võimaldada vajadusel osalist kasutamist.
English: Clinical trials with filgrastim have included a small number of elderly patients but special studies have not been performed in this group and therefore specific dosage recommendations cannot be made.
Estonian: Filgrastiimiga teostatud kliinilistes uuringutes on osalenud väike arv eakaid patsiente, kuid selle rühmaga ei ole spetsiaalseid uuringuid läbi viidud ja seetõttu ei saa spetsiifilisi annustamissoovitusi esitada.
English: In other circumstances, additional leukaphereses may be necessary.
Estonian: Muudel juhtudel võivad olla vajalikud täiendavad leukafereesid.
English: • lungs do not function as they should, causing breathlessness (respiratory failure)
Estonian: • kopsud ei tööta nii nagu peavad, põhjustades õhupuudust (hingamispuudulikkus)
English: For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient.
Estonian: Patsientide puhul, kes ei ole saanud ulatuslikku kemoteraapiat, piisab sageli ühest leukafereesist.
English: It can also be given as a daily slow injection into the vein (known as an intravenous infusion).
Estonian: Seda võib manustada ka igapäevase aeglase süstena veeni (tuntud intravenoosse infusioonina).
English: You should talk to your doctor about your risks of developing cancers of the blood and what testing should be done.
Estonian: Te peate arstile rääkima oma verevähi tekkimise riskidest ja analüüsidest, mida tuleb teha.
English: Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present.
Estonian: Nagu kõikide bioloogiliste ainete puhul on eeldatav, võivad tekkida seonduvad antikehad, kuid praeguseks ei ole neid seostatud neutraliseeriva toimega.
English: Transfusion reactione a See section c (Description of selected adverse reactions)
Estonian: Vereülekande reaktsioone a Vt lõik c (valitud kõrvaltoimete kirjeldus).
English: The usual dose varies depending on your illness and weight.
Estonian: Tavaline annus sõltub teie haigusest ja kehakaalust.
English: Possible interactions with other haematopoietic growth factors and cytokines have not yet been investigated in clinical trials.
Estonian: Võimalikke koostoimeid teiste hematopoeetiliste kasvufaktorite ja tsütokiinidega ei ole kliiniliste uuringute käigus kindlaks tehtud.
English: The efficacy of treatment was clear for this age-group, which included most patients with congenital neutropenia.
Estonian: Ravi efektiivsus ilmnes selgelt selles vanusegrupis, kuhu kuulus kõige enam kaasasündinud neutropeeniaga patsiente.
English: Your doctor may want to monitor you closely, see section 4 of the package leaflet.
Estonian: Teie arst võib pidada vajalikuks teie hoolikat jälgimist, vt infolehe lõik 4.
English: The recommendation of a minimum yield of ≥ 2.0 x 106 CD34+ cells/kg is based on published experience resulting in adequate haematologic reconstitution.
Estonian: Minimaalne soovitatav kogus ≥ 2,0 × 106/CD34+ rakku/kg põhineb avaldatud kogemustel saavutatud adekvaatse hematoloogilise taastumise kohta.
English: However, you should not attempt this unless you have been properly trained first by your health care provider.
Estonian: Kuid ärge proovige seda teha, kui tervishoiutöötaja pole teile seda korralikult õpetanud.
English: The results of flow cytometric analysis of CD34+ cell numbers vary depending on the precise methodology used and, recommendations of numbers based on studies in other laboratories need to be interpreted with caution.
Estonian: CD34+ rakkude voolutsütomeetrilise analüüsi tulemused varieeruvad, sõltuvalt konkreetsest kasutatud metoodikast, ja eri laboratooriumides teostatud uuringutel põhinevaid soovitusi tuleb tõlgendada ettevaatusega.
English: Timing of leukapheresis: 1 or 2 leukaphereses on days 5 and 6 are often sufficient.
Estonian: Leukafereesi ajad: sageli piisab 1 või 2 leukafereesist, mis teostatakse 5. ja 6. päeval.
English: Haematuria was common and proteinuria occurred in a small number of patients.
Estonian: Hematuuria esines sageli ja proteinuuria esines vähesel hulgal patsientidest.
English: The only consistently reported adverse event was musculoskeletal pain‚ which is no different from the experience in the adult population.
Estonian: Ainuke pidevalt esinev kõrvaltoime oli lihas-skeleti valu, mis ei erine täiskasvanutega saadud kogemustest.
English: The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics [t(8;21), t(15;17), and inv(16)] have not been established.
Estonian: Filgrastiimi ohutus ja efektiivsus ei ole tõestatud alla 55-aastastel de novo ägeda müeloidleukeemiaga patsientidel, kellel on head tsütogeneetilised näitajad (t(8;21), t(15;17) ja inv(16)).
English: Causes of transient neutropenia, such as viral infections should be excluded.
Estonian: Muud mööduva neutropeenia põhjused, näiteks viirusinfektsioonid, peavad olema välistatud.
English: Preliminary evidence from a small number of patients treated concomitantly with filgrastim and 5-fluorouracil indicates that the severity of neutropenia may be exacerbated.
Estonian: Esialgsed andmed väikese arvu patsientide kohta, kes on saanud ravi samaaegselt filgrastiimi ja 5-fluorouratsiiliga, näitavad, et neutropeenia raskusaste võib ägeneda.
English: However, the administration of melphalan, carboplatin or BCNU together with filgrastim has been shown to be effective for progenitor mobilisation.
Estonian: Sellegipoolest on tõestatud, et melfalaani, karboplatiini või BCNU manustamine koos filgrastiimiga on efektiivne progenitoorrakkude mobilisatsiooni seisukohalt.
English: There is some evidence from a study of single dose administration that intravenous dosing may shorten the duration of effect.
Estonian: Teatavad andmed uuringust ühekordse annuse manustamise kohta on näidanud, et intravenoossel manustamisel võib toime kestus lüheneda.
English: • before high-dose chemotherapy to make the bone marrow produce more stem cells which can be collected and given back to you after your treatment.
Estonian: • enne suurte annustega keemiaravi, et panna luuüdi tootma rohkem tüvirakke, mida saab organismist koguda ja pärast ravi teile tagasi kanda.
English: Filgrastim HEXAL is a white blood cell growth factor (granulocyte colony stimulating factor) and belongs to a group of proteins called cytokines.
Estonian: Filgrastim HEXAL on vere valgeliblede kasvufaktor (granulotsüütide kolooniat stimuleeriv faktor) ja kuulub valkude rühma, mida nimetatakse tsütokiinideks.
English: • unusual change in the urine
Estonian: • ebatavaline muutus uriinis
English: MDS and leukaemias are natural complications of the disease and are of uncertain relation to filgrastim therapy.
Estonian: MDS ja leukeemiad on haiguse loomulikud tüsistused ning nende seos filgrastiimiga on ebaselge.
English: Some cases of splenic rupture were fatal (see section 4.4).
Estonian: Mõned põrnarebendi juhtumid lõppesid surmaga (vt lõik 4.4).
English: If yields are inadequate, as measured by the criteria above, alternative forms of treatment not requiring progenitor support should be considered.
Estonian: Kui saadud kogus on väiksem eelpool mainitud kriteeriumitega mõõdetud miinimumist, tuleb kaaluda alternatiivseid ravivõimalusi, mis ei nõua progenitoorrakkude siirdamist.
English: Other blood cell changes occur, including anaemia and transient increases in myeloid progenitors, which require close monitoring of cell counts.
Estonian: Tekib ka muid muutusi vererakkudes, sealhulgas aneemia ja mööduvad müeloidsete progenitoorrakkude arvu suurenemised, mis nõuavad verepildi hoolikat jälgimist.
English: Pack sizes of 1, 3, 5 or 10 pre-filled syringes.
Estonian: Pakendis on 1, 3, 5 või 10 süstlit.
English: These could be symptoms of a condition called “Capillary Leak Syndrome” which causes blood to leak from the small blood vessels into your body and needs urgent medical attention.
Estonian: Need võivad olla sümptomid seisundile, mida nimetatakse kapillaaride lekke sündroomiks; see põhjustab vere lekkimist väikestest veresoontest teie kehasse ja vajab kiiresti arstiabi.
English: Absolute neutrophil count (ANC) should be monitored closely, especially during the first few weeks of filgrastim therapy.
Estonian: Neutrofiilide absoluutarvu (ANC) peab hoolikalt jälgima, eriti filgrastiim-ravi esimestel nädalatel.
English: The subcutaneous route is preferred in most cases.
Estonian: Enamikul juhtudel on eelistatav subkutaanne manustamistee.
English: Filgrastim HEXAL can be used:
Estonian: Filgrastim HEXAL'i saab kasutada:
English: In order to improve the traceability of granulocyte-colony stimulating factors (G-CSFs), the trade name of the administered product should be clearly recorded in the patient file.
Estonian: Parandamaks granulotsüütide kolooniat stimuleerivate faktorite (G-CSF-id) jälgitavust, tuleb manustatava preparaadi tootenimi selgelt märkida patsiendi tervisekaardile.
English: • in patients with advanced HIV infection which will help reduce the risk of infections.
Estonian: • kaugelearenenud HIV-infektsiooniga patsientidel, et aidata vähendada nakkuste ohtu.
English: The mobilisation and apheresis procedures should be performed in collaboration with an oncologyhaematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Estonian: Mobilisatsiooni ja afereesi protseduure tuleb teostada koostöös hematoloogia-onkoloogia keskusega, millel on piisav kogemus sellel alal ja kus on võimalik korrektselt läbi viia hematopoeetiliste progenitoorrakkude hindamist.
English: Each graduation ring corresponds to a volume of 0.1 ml.
Estonian: Iga jaotusring vastab mahule 0,1 ml.
English: Other special precautions
Estonian: Teised erilised ettevaatusabinõud
English: Other medicines and Filgrastim HEXAL
Estonian: Muud ravimid ja Filgrastim HEXAL
English: The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 72 hours (but not above 25°C).
Estonian: Süstli tohib külmkapist välja võtta ja jätta toatemperatuurile ühekordselt maksimaalselt 72 tunniks (hoituna temperatuuril kuni 25°C).
English: Please tell your doctor before starting treatment if you have: - osteoporosis (bone disease); - sickle cell anaemia, as Filgrastim HEXAL may cause sickle cell crisis.
Estonian: Rääkige oma arstile enne ravi alustamist, kui teil on: - osteoporoos (luuhaigus); - sirprakuline aneemia, sest Filgrastim HEXAL võib põhjustada sirprakulise aneemia kriisi.
English: Use each syringe only for one injection.
Estonian: Kasutage iga süstlit ainult üheks süstiks.
English: Your doctor may regularly test your urine if you experience this side effect or if protein is found in your urine (proteinuria).
Estonian: Arst võib teile korrapäraselt määrata uriinianalüüse, kui teil tekib see kõrvaltoime või kui teie uriinist leitakse valku (proteinuuria).
English: How long will I have to take Filgrastim HEXAL?
Estonian: Kui kaua ma pean Filgrastim HEXAL'i saama?
English: Contents of the pack and other information What Filgrastim HEXAL contains
Estonian: Pakendi sisu ja muu teave Mida Filgrastim HEXAL sisaldab
English: If you become pregnant during Filgrastim HEXAL treatment, please inform your doctor.
Estonian: Kui rasestute Filgrastim HEXAL-ravi ajal, teatage sellest oma arstile.
English: • disease which causes bones to become less dense, making them weaker, more brittle and likely to break (osteoporosis)
Estonian: • haigus, mis põhjustab luutiheduse vähenemist ja muudab luud nõrgemaks, rabedamaks ja kergemini murduvaks (osteoporoos)